1078 Randomized comparison of Etoposide-Cisplatin vs Etoposide-Carboplatin and irradiation in small cell lung cancer (SCLC): Evaluation of long term survival

Between 2/88 and 5/91, 143 patients (pts) with SCLC (82 extensive and 61 limited disease) were randomized to receive Cisplatin and Etoposide (PE) or Carboplatin and Etoposide (CE). Responders, received concurrently with the 3rd cycle of chemotherapy chest irradiation, while CR's received additi...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 31; pp. S22 - S23
Main Authors:	Samantas, E., Milonakis, M., Klouvas, G., Panoussaki, A., Agelidou, M., Palamidas, F., Boleli, E., Kosmas, E., Papadakis, E., Kiamouris, N., Vardoulakis, T., Kosmidis, P., Pavlidis, N., Foutzilas, G., Skarios, D.V.
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01-11-1995
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Between 2/88 and 5/91, 143 patients (pts) with SCLC (82 extensive and 61 limited disease) were randomized to receive Cisplatin and Etoposide (PE) or Carboplatin and Etoposide (CE). Responders, received concurrently with the 3rd cycle of chemotherapy chest irradiation, while CR's received additionally prophylactic cranial irradiation. No statistically significant difference was observed in the response and survival between the two groups (Sem. Oneal. 21:23–30,1994, suppl.6). A recent analysis oflong term survival pts, showed that 10 pts of the PE group and 9 of the CE group lived more than 2 years. Patients were similarly stratified according to the stage of the disease, PS, sodium, alkaline phosphatase and albumin. Response CR Survival (months) TTl (months) PE 90% 80% 45.7 (28.1–69.0) 43.90 (4–69) CE 100% 67% 48.4 (27.6–76.7) 23.48 (3–77) None of the above differences was found to be statistically significant. Eleven pts have died so far from SCLC and I pt from NSCLC respectively. Seven pts (5 PE, 2 CE) are still alive from 42+ to 77+ months. In conclusion it appears that the less toxic Carboplatin is at least equally effective to Cisplatin as far as it concerns response, duration of responses and long term survival, in pts with SCLC.
ISSN:	0959-8049 1879-0852
DOI:	10.1016/0959-8049(95)95352-7